The company’s new advancements could lead to new product introductions and revenue in areas not contemplated by us previously, thus enhancing the value that much more.
Download Report in PDF Or Scroll down to read the complete report below.
The Company’s colonoscope initiative is making huge strides on the developmental side and will also include a series of six-figure milestone payments from its partner, Haemoband Surgical in the near term. Phase Two of the colonoscope application development, which includes the production of working prototypes to be used for in-lab testing and testing of completed systems, will be concluded by the end of September. The Phase Two development includes refinements to the sensor, completion of the development of the electronics package to accompany the scope and colonoscope device, which uses Flexpoint's patented Bend Sensor® technology to monitor the device's position as it is administered to the patient.
Also at the end of September, Phase Three will commence. The final phase will include several working colonoscope devices and the associated electronics in preparation for successful medical trials and gathering the information necessary for completion of the required governmental certifications.
It is anticipated that the device will initially be approved for use in Europe and use will expand to the U.S. market as the necessary approvals are obtained. It is expected that the needed certifications in Europe can be completed by late this year or early next year.
There is pent-up demand for inexpensive, accurate methods of determining the position of the colonoscopes around the world, and Haemoband's device is the first of its class. Testing to date has demonstrated the ability of Flexpoint's sensor to graphically display the shape of the colonoscope and to accurately detect any looping of the scope. With more accurate readings on the position of the device, doctors can minimize complications that can arise from the colonoscope coiling, and can cut down on the time necessary to perform the procedure. With the incorporation of the disposable Bend Sensor, the current monitoring equipment can now graphically display the position and formation of the colonoscope. This is a distinct advantage over the capabilities of the existing equipment.
With 5 million colonoscopies performed in the U.S. annually, and a similar number in Europe, the market opportunity for Flexpoint is huge. We believe that production could begin in 1H14. At full production, this is the most promising consistent revenue stream with annual volumes in the millions. Completion of development of the colonoscope will lead to development of other related medical devices with even greater annual usage.
Separately, Flexpoint and Bend Tech LLC announced that they have received funding for the development of a "Smart Shoe" that shows real time data and has the ability to collect data for future training and comparisons. Flexpoint in conjunction with Bend Tech has developed a shoe that can communicate with smart phones and other wireless devices to give real time analysis showing balance, performance and other pertinent data relating to performance of the individual. Golf will be the first targeted industry, but successful entry into this segment opens a number of other areas for development as this technology can be replicated for use in virtually any sports and recreational activity. Golfers and other sports enthusiasts spend billions of dollars annually in an effort to improve their individual performance. Flexpoint could hit a home run in this highly profitable and fast-growing vertical market by offering an inexpensive technology for that purpose to millions of potential customers.
Representatives of Bend Tech are currently involved in ongoing discussions and negotiations with several major equipment manufacturers and distributors and Flexpoint management anticipates that development of the golf shoe product could be completed and the product brought to market by the middle of next year. The next step will be to build advanced prototypes for demonstration purposes and then take the shoe to various manufacturers to work out either a manufacturing agreement or a licensing agreement for production of the shoe and related electronics.
We believe that real traction will occur after the turn of the year as the two companies upgrade electronics and visual displays of the offering for the all-important PGA merchandise show January 21-24 in Orlando, Florida. It is likely that meaningful business development and production opportunities could be closed after the show. Several prototypes of the shoes and even golf club shafts with sensors have already been completed and demonstrated to major equipment manufacturers.
With a series of milestones ahead, the undervalued FLXT stock offers huge potential for both the stock trader and the long term investor. With projected gross margins north of 50%, we believe that FLXT could earn nearly $2M in net income on $6-7M in revenue once broad automotive product deployment occurs. This event would likely result in a $30-40M market cap, versus the ridiculously low $5M current market value. We rate FLXT Speculative Buy with a $0.20 price target.
Recent Trading History For FLXT
You Might Also Like
Senior Analyst: Robert Goldman
Rob Goldman founded Goldman Small Cap Research in 2009 and has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.
Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
This Opportunity Research report was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. While stocks in the Opportunity format may have a higher risk profile, they typically offer greater upside as well. Goldman Small Cap Research has been compensated by a third party in the amount of $8,000 for a three-month research subscription service. The Firm does not accept any equity compensation. All information contained in this report was provided by the Company via filings, brochures, spec sheets, etc. and our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This report does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com